(Finance) – Roche received the via ibera of the Food and Drugs Administrationthe U.S. Medicines Authority, for the treatment of influenza in children aged five and over with flu shot Xofluza.
The medicine has been approved for the treatment of acute influenza in healthy children who have been showing symptoms for no more than 48 hours. The FDA has also approved Xofluza to prevent influenza in children 5 years and older following contact with an infected person.
Xofluza, already approved by the FDA for the treatment of influenza in children aged 12 and over, becomes the first single-dose oral flu medicine approved in the United States even in children of this age group.